US regulatory status: approved. Molecular target: Integrin alpha-IIb/beta-3.
- Target
- Integrin alpha-IIb/beta-3
- Mechanism
- Integrin alpha-V/beta-3 inhibitor
biotech · Amyotrophic Lateral Sclerosis (ALS) · Amyotrophic Lateral Sclerosis · BCLI
BRAINSTORM CELL THERAPEUTICS
BRAINSTORM CELL THERAPEUTICS INC.
BRAINSTORM CELL THERAPEUTICS drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
NEW YORK, NY, USA HQ
2004 Founded
30 Employees
Public company Type
BCLI · NYSE Ticker
Company details
- Status
- Public
- HQ
- NEW YORK, NY, USA
- Founded
- 2004
- Employees
- 30
- Programs
- 5
- Drugs
- 5
- Patents
- 8
BRAINSTORM CELL THERAPEUTICS pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BRAINSTORM CELL THERAPEUTICS drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to BRAINSTORM CELL THERAPEUTICS in public FDA and regional records.
-
Development asset linked to BRAINSTORM CELL THERAPEUTICS in public FDA and regional records.
-
Development asset linked to BRAINSTORM CELL THERAPEUTICS in public FDA and regional records.
-
Development asset linked to BRAINSTORM CELL THERAPEUTICS in public FDA and regional records.